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ABSTRACT
Endoesophageal brachytherapy is a useful technique for the 
palliative treatment of dysphagia in advanced oesophageal cancer. This 
technique offers good results on dysphagia control and quality of life. 
We report the case of a patient treated with this technique presenting 
complete response to the dysphagia. We describe endoesophageal 
brachyterapy technique and we comment on the literature.
Key words: Palliative endoesophageal brachytherapy. Dysphagia. 
Oesophageal cancer.
INTRODUCTION
Oesophageal cancer is an aggressive disease which is usu-
ally diagnosed in advanced stages. The prognosis is poor (10-
15% survival at 5 years) (1) and dysphagia is a common com-
plication in advanced stages and the quality of life of patients 
in terminal/advanced phases of this disease is poor when dys-
phagia is present. Thus, once the diagnosis is made palliation 
is the primary objective, with various treatment options being 
available (2). In many cases high-dose rate endoesophageal 
brachytherapy is one of the best options. This radiotherapy 
technique involves the introduction of a radioactive source into 
the applicator through the specific tumour site to be treated. 
This allows a high dose in the endoluminal tumour component 
with little impact on neighbouring healthy tissues (1,3).
CASE REPORT
The patient was a 62-year-old woman, able to carry out 
daily life activities autonomously, with no previous medi-
cal history of interest.
The patient presented with liquids dysphagia for which 
a gastroscopy was performed showing a bleeding poly-
poid tumor in the middle third of the oesophagus. The 
tumour was 25 cm from the teeth affecting 45 degrees 
of the oesophageal wall and the cardias was not affect-
ed. Squamous carcinoma was diagnosed by pathological 
analysis of the tumour biopsy. A oesophagogram (Fig. 1) 
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Fig. 1. Oesophagogram with barium contrast showing tumoural stenosis 
in the oesophageal middle third with proximal dilatation.
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showed a tumour in the middle third of the oesophagus 
and a wide upper oesophageal dilatation above the tumour. 
Oesophageal ultrasonography showed a tumour affecting 
the adventitia. Computed thoracoabdominal tomography 
(CT) revealed a node in the mediastinum and hepatic and 
lung metastases. 
The patient was staged as T3N1M1 and started chemother-
apy based on cisplatin and 5-fluouracil, with partial response 
of the oesophageal tumour and pulmonary and hepatic metas-
tases after 3 cycles. After completing 6 cycles progression of 
oesophageal and lung tumour metastases was observed with 
stabilization of the remaining hepatic metastases. 
Thereafter, the patient presented important liquids dys-
phagia and vomiting after feeding due to stenosis leading 
to weight loss of 3 kg. Her performance state was 0 and she 
was considered to receive endoesophageal brachytherapy. 
Before brachytherapy, CT (Fig. 2) and ultrasonography 
were performed in order to determine the size and tumour 
characteristics and the possibility of oesophageal fistula 
that could contraindicate the procedure. Following the 
rules of the American Brachytherapy Society (ABS) (4) 
a total of 18 Gy in 3 fractions at 6 Gy per fraction were 
considered as treatment.
The procedure of each treatment was as follows:
1.  Oesophageal gastroscopy was performed under 
sedation for applicator placement in the Endosco-
py Unit at our hospital. A circumferential stenotic 
tumour was detected at 24 cm to 33 cm from the 
teeth hindering the passage of a 10 mm gastroscopy 
tube (Fig. 3A). During the gastroscopy an Amplatz 
flexible metallic guide was introduced and the gas-
troscope was then removed maintaining the position 
of the guide. Using this guide a 10 mm in diameter 
Bonvoisin brachytherapy applicator (Nucletron®) 
was introduced with the following characteristics: 
a) A central lumen to allow its passage through the 
metallic guide into the oesophagus and also the intro-
duction of a radioactive source for treatment once the 
brachytherapy dosimetric study had been performed; 
and b) marks on its surface every 10 mm to allow 
the applicator to remain in a determined position in 
Fig. 2. Sagittal and coronal CT reconstruction showing a concentric thick-
ening of the oesophageal wall from the carina to the gastrooesophageal 
junction. Multiple bilateral lung and hepatic metastases.
Fig. 3. A. Gastroscopy before treatment: Bleeding polypoid tumour affect-
ing 45 degrees of the oesophageal wall. B. Gastroscopy after treatment: 
Disappearance of oesophageal tumour. Scar area at 8 hours.
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relation to the teeth to treat the tumour with a safety 
margin (Fig. 4A). Finally, the applicator was fixed 
to the face skin at an appropriate distance from the 
teeth. 
2.  Treatment planning. The patient was referred to the 
Radiation Oncology Department where the correct 
placement of the applicator was confirmed in rela-
tion to the teeth. A radiolucent dummy source with 
marks every 10 mm was introduced into a transfer-
ence tube inside the applicator. A 1 mm slice CT was 
obtained for brachytherapy treatment planning with 
the patient in the same position as during the gas-
troscopy procedure. Images were transferred to the 
planning system (Oncentra Braqui v. 4.1, Nucletron-
Elekta®). The tumour to be treated and the organs 
at risk such as vessels, heart and spinal cord were 
defined in each CT slice. In this case the bronchi 
were far from the applicator and were therefore not 
included in the study. A dosimetric study was per-
formed to administer 6 Gy 5 mm from the applicator 
surface in each of the 3 treatments with an active 
source length of 11 cm (Fig. 4B).
3.  Treatment. The patient was transferred to a radio-
protected room where after removal of the dummy 
source the transference tube was connected to a 
source transference machine (microHDR, Nucle-
tron®) to undergo treatment with a high-dose-rate 
(HDR) 192-Iridium source. After confirmation of the 
correct position of the applicator the treatment was 
started inside the radioprotected room. During the 10 
minutes of treatment the patient was monitored with 
external TV and radiophonic systems. On comple-
tion of the treatment the transference tube and appli-
cator were uneventfully removed and the patient was 
discharged 3 hours later. The remaining 2 treatments 
were performed on a weekly interval basis as previ-
ously described.
Evolution: Following the second treatment the patient 
reported an improvement in the dysphagia which com-
pletely disappeared at 4 weeks after the initiation of treat-
ment. Since then she has followed a normal diet with a 
progressive increase in weight of 6 kg. Treatment response 
was evaluated by clinical manifestations and the use of 
gastroscopy (Fig. 3B), with endoesophageal ultrasonog-
raphy and chest CT scan also being performed. 
After brachytherapy the patient received second line 
chemotherapy (docetaxel 75 mg/m2 weekly) with pro-
gression of metastases after 3 cycles. At four moths after 
brachytherapy the patient died due to a sepsis and was free 
of dysphagia.
DISCUSSION
Endoesophageal brachytherapy was first described in 
1909 by Barçat and Guisez using radium candles (5), and 
in 1976 the first series using a HDR 192-Iridium source (6) 
was described in the literature. Despite the technique is not 
new and different studies have shown its efficacy in pal-
Fig. 4. A. Bonvoisin endooesophageal applicator of 10 y 13 mm in diam-
eter. One with a source transference tube inside. B. CT planning with the 
applicator. C. Dosimetric study showing dose distribution in axial, coronal 
and sagittal slices showing a D90 isodose involving the tumour (outlined 
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liative oesophageal cancer treatment, its use has not been 
extended for different reasons: The lack of HDR source 
projectors in most centres, the lack of specific applica-
tors considering their cost and a lack of knowledge of the 
technique. Moreover, the tendency to use a laser technique, 
endoesophageal prosthesis or gastrostomy in the treatment 
of dysphagia has made its use less extensive. The low num-
ber of patients, their low life expectancy, the fear of com-
plications due to the technique despite being less frequent 
than in other palliative techniques have also contributed 
to its lesser use.
Palliative oesophageal cancer treatment of dysphagia 
can be done with oesophagectomy or oesophageal by-pass; 
nevertheless, although the palliation is successful, the mor-
tality and morbidity are high. Less aggressive options such 
as gastrostomy impede oral intake, and prostheses and dila-
tations are not without complications (2). Laser and pho-
todynamic treatments require hospitalisation and induce 
problems related to sun exposure. External beam irradia-
tion (EBI) needs high radiation doses with the consequent 
daily attendance to the hospital and has complications 
including dysphagia and mucositis. All these techniques 
are effective considering the life expectancy, dysphagia 
free-interval, treatment related complications and quality 
of life if applied to the appropriate patient. 
Endoesphageal brachytherapy is a rapid effective tech-
nique in controlling dysphagia and hematemesis, treating 
the endoluminal tumour component with low doses to the 
neighbouring healthy tissues. This treatment can be admin-
istered in previously irradiated patients or in those with 
clinical progression after a prosthesis and laser treatment 
(7-9). The indications and contraindications of this tech-
nique are presented in table I (3,4).
The use of HDR sources allows the administration of 
high doses in a short time; the consequence is the need to 
fractionate the treatment to avoid acute and late compli-
cations. The number of fractions for palliative treatments 
ranges between 1 to 3 fractions with doses of between 
4 Gy to 15 Gy per fraction depending on the schedule, 
patient characteristics, life expectancy and the protocol of 
each centre (10). In general, for palliative treatments doses 
higher than 18-20 Gy (3 fractions of 6-7Gy) are not rec-
ommended considering that an increased of acute and late 
complications has been described (4). In the present case 
the good status of the patient led to the administration of 
3 fractions of 6 Gy to allow prolonged palliation.
The results on dysphagia palliation in the literature 
describe responses between 70% and 90%, with dyspha-
gia-free-intervals of 2 to 9 months and a mean survival of 
4 to 14 months (1,3,10,11). In the present case the patient 
had distant metastases with progression after chemother-
apy and died after 4 months free of dysphagia and after 
having increased her weight by 6 kg.
In a phase III study 219 patients were randomised to 
receive exclusive EBI (30 Gy in 10 fractions) vs. the same 
regime plus 2 endoesophageal brachytherapy applications 
of 8 Gy each. The dysphagia-free interval was superior in 
the combined brachytherapy treatment with benefits in the 
degree of dysphagia, regurgitation, chest pain and perfor-
mance status (absolute benefit of 18%) (9).
we would like to remark another randomised phase III 
by Homs et al. in which 209 patients were randomised to 
receive one brachytherapy fraction of 12 Gy vs. stent, to 
analyse the results in dysphagia, complications, relapses 
and costs. Dysphagia response was faster with stent, 
nevertheless after 30 days results on complications and 
dysphagia-free interval and quality of life where superior 
for patients treated with brachytherapy; there were no dif-
ferences in cost and overall survival (12,13). The authors 
concluded that endoesophageal brachytherapy should be 
the treatment of choice for dysphagia palliation. This treat-
ment should probably be considered in patients with a good 
performance status and a life expectancy of greater than 
2 months (14). Moreover, brachytherapy treatment does 
not impede posterior placement of a stent. 
Considering the low life expectancy in palliative cases, 
long term complications should not be expected, with 
their appearance occurring in long term survivors. The 
incidence of complications can vary among series and 
are mainly associated with high doses per fraction and 
appear after 6 months. The most usual complications are 
ulcers (3-28%), different degrees of stenosis that may be 
due to tumour progression or treatment-related fibrosis 
(2-44%), fistula due to tumour progression in half of the 
Table I. Indications and contraindications in palliative endoesophageal brachytherapy
Indications Contraindications
Tumour <  10 cm length Tumour > 10 cm length
Tumour confined to oesophageal wall Involvement of superior oesophageal third and cardias
Thoracic oesophagus No possibility of gastroscopy (stenosis...)
No lymphatic and  distant metastasis (optional) Tracheoesophageal fistula
Life expectancy > 2 months Extraoesophageal and/or lymph node involvement
Vol. 107, N.º 7, 2015 ENDOLUMINAL BRACHyTHERAPy IN THE TREATMENT OF OESOPHAGEAL CANCER. TECHNIQUE 453
 DESCRIPTION, CASE REPORT AND REVIEw OF THE LITERATURE
Rev esp enfeRm Dig 2015; 107 (7): 449-453
cases (2-17%) and haemorrhage (6-8%) (3,10,12,14,15). In 
any case, a similar incidence of complications is observed 
after EBI series. 
The present case showed complete response of dys-
phagia, with no treatment-related complications, and the 
patient was able to return to normal food intake increasing 
her weight by 6 kg and presenting a good quality of life 
until she died. 
In conclusion, endoesophageal brachytherapy offers 
clear advantages in the palliative treatment of dysphagia 
considering its high number of responses. Treatment can 
be performed on an outpatient basis, and it is well tolerated 
with a feasible oral intake several hours later. The toxicity 
is lower than with other treatment modalities and it can be 
performed before or after other palliative treatments. The 
impact on the life quality of the patients is clear as dem-
onstrated in the present case and it is cost/effective from 
the economic point of view. Considering all these aspects 
endoesophageal brachytherapy should be considered the 
treatment of choice when indicated. 
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